Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
propranolol + sintilimab + chemotherapy
- Development stage
- Phase 1
- Lead developer
- The Second Xiangya Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This investigational combination therapy is being evaluated as a first-line treatment for advanced non-small cell lung cancer (NSCLC) that is negative for EGFR, ALK, and ROS1 driver mutations. The regimen consists of **propranolol hydrochloride**, a non-selective beta-adrenergic receptor antagonist; **sintilimab**, a recombinant humanized IgG4 monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor; and standard **platinum-based chemotherapy** (typically cisplatin or carboplatin combined with pemetrexed, paclitaxel, or gemcitabine). Propranolol is included to potentially modulate the tumor microenvironment and augment immune cell responses, thereby enhancing the efficacy of the immune checkpoint inhibitor sintilimab. The combination is currently under investigation in a Phase I clinical trial (BRIO) sponsored by the Second Xiangya Hospital of Central South University.
- Other names
- propranolol hydrochloride in combination with sintilimab and platinum-based chemotherapy
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)ADRB1 (β1)ADRB2 (β2)
Beyond the preview
Go deeper on propranolol + sintilimab + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on propranolol + sintilimab + chemotherapy.